New studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing encouraging outcomes in treating excess mass and related second-type diabetes. Preclinical evidence suggest a unique action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/